Bellevue Group AG
- SEC CIK
- 0001674546
- Latest filing
- Aug 14, 2026
Holdings in Q3 2021
Holdings as of Sep 30, 2021, filed Nov 12, 2021. Long positions only; changes compare share counts with Q2 2021.
- Positions
- 219
- +6 vs. Q2 2021
- Portfolio value
- $9.85B
- −$390.3M (−3.8%) vs. Q2 2021
| Security | Class | Shares | Value | % of portfolio | Share change | Action | History |
|---|---|---|---|---|---|---|---|
| DHRDanaher Corp | Stock | 456,679 | $139.0M | 1.4% | −26,261−5.4% | Reduced | History |
| ITCIIntra-Cellular Therapies, Inc. | COM | 3,773,919 | $140.7M | 1.4% | +164,000+4.5% | Added | History |
| SAGESage Therapeutics, Inc. | COM | 3,209,004 | $142.2M | 1.4% | +844,800+35.7% | Added | History |
| DXCMDexcom Inc | COM | 263,839 | $144.3M | 1.5% | +19,063+7.8% | Added | History |
| BIIBBiogen Inc. | COM | 527,000 | $149.1M | 1.5% | −1,100−0.2% | Reduced | History |
| ABTAbbott Laboratories | Stock | 1,387,499 | $163.9M | 1.7% | +10,000+0.7% | Added | History |
| ELVElevance Health, Inc. | Stock | 475,210 | $177.2M | 1.8% | +9,234+2.0% | Added | History |
| MGNXMacrogenics Inc | COM | 8,544,597 | $178.9M | 1.8% | +1,168,571+15.8% | Added | History |
| ARVNArvinas, Inc. | COM | 2,241,403 | $184.2M | 1.9% | +4,000+0.2% | Added | History |
| FATEFate Therapeutics Inc | COM | 3,238,036 | $191.9M | 1.9% | +624,500+23.9% | Added | History |
| AGIOAgios Pharmaceuticals, Inc. | COM | 4,341,992 | $200.4M | 2.0% | −11,000−0.3% | Reduced | History |
| ISRGIntuitive Surgical Inc | COM NEW | 203,595 | $202.4M | 2.1% | +1,500+0.7% | Added | History |
| INCYIncyte Corp | COM | 2,957,000 | $203.4M | 2.1% | −14,400−0.5% | Reduced | History |
| ALNYAlnylam Pharmaceuticals, Inc. | COM | 1,408,418 | $265.9M | 2.7% | −140,674−9.1% | Reduced | History |
| NBIXNeurocrine Biosciences Inc | Stock | 3,004,051 | $288.1M | 2.9% | −13,700−0.5% | Reduced | History |
| ARGXArgenx SE | SPONSORED ADR | 983,938 | $297.1M | 3.0% | +9,900+1.0% | Added | History |
| IONSIonis Pharmaceuticals Inc | COM | 9,347,926 | $313.5M | 3.2% | −582,319−5.9% | Reduced | History |
| VRTXVertex Pharmaceuticals Inc | Stock | 1,761,616 | $319.5M | 3.2% | +27,922+1.6% | Added | History |
| MRNAModerna, Inc. | Stock | 1,727,349 | $664.8M | 6.7% | −814,951−32.1% | Reduced | History |
Options (1)
Puts and calls in the same filing. Amounts are the market value of the underlying shares, which is what 13F reports.
| Security | Class | Puts | Calls |
|---|---|---|---|
| Curevac N VN2451R105 | COM | – | $1.00K |
Sold out since Q2 2021 (7)
Positions held at the end of Q2 2021 that are gone from this filing.
| Security | Class | Shares in Q2 2021 | Value in Q2 2021 | % of portfolio in Q2 2021 | History |
|---|---|---|---|---|---|
| EAREargo, Inc. | COM | 434,054 | $17.3M | 0.2% | History |
| XENTIntersect ENT, Inc. | COM | 617,968 | $10.6M | 0.1% | History |
| SGFYSignify Health, Inc. | CL A COM | 200,000 | $6.09M | 0.1% | History |
| ALXNAlexion Pharmaceuticals, Inc. | COM | 14,300 | $2.63M | <0.1% | History |
| DRNADicerna Pharmaceuticals Inc | COM | 61,000 | $2.28M | <0.1% | History |
| ACADAcadia Pharmaceuticals Inc | COM | 65,900 | $1.61M | <0.1% | History |
| RXRXRecursion Pharmaceuticals, Inc. | CL A | 20,000 | $730.0K | <0.1% | History |